Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MultipleMS

Financiado

Cerrado

Multiple manifestations of genetic and non genetic factors in Multiple Sclerosis...

Multiple manifestations of genetic and non genetic factors in Multiple Sclerosis disentangled with a multi omics approach to accelerate personalised medicine The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progres... ver más

30/06/2023

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 24 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-06-30

SC1-PM-01-2016: Multi omics for personalised therap...

I+D

Cerrada hace 8 años

0% 98% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

24 Participantes

2.94M€ | Lider

AGILE CONTENT

494.98K€ | Participante

TUM-MED

1.79M€ | Participante

SARD

7.13K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121243-I00 PLATAFORMA DELFOS: SISTEMA DE INFORMACION PARA LA GESTION DE... 102K€ Cerrado

GAIA-Health GAIA Health microbiome suite for personalized medicine 71K€ Cerrado

PRE2019-089807 REVISANDO LA REPLICABILIDAD GENETICA MEDIANTE UN ENFOQUE MUL... 98K€ Cerrado

MLPM2012 Machine Learning for Personalized Medicine 4M€ Cerrado

MULTIMOD Multi layer network modules to identify markers for personal... 4M€ Cerrado

BEST MS Best EScalation Treatment in Multiple Sclerosis MS 6M€ Cerrado

Duración del proyecto: 78 meses Fecha Inicio: 2016-12-12
Fecha Fin: 2023-06-30

Líder del proyecto

KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The complex interactions between genetic and non-genetic factors produce heterogeneities in patients as reflected in the diversity of pathophysiology, clinical manifestations, response to therapies, disease development and progression. Yet, the full potential of personalized medicine entails biomarker-guided delivery of efficient therapies in stratified patient populations. MultipleMS will therefore develop, validate, and exploit methods for patient stratification in Multiple Sclerosis, a chronic inflammatory disease and a leading causes of non-traumatic disability in young adults, with an estimated cost of €37 000 per patient per year over a duration of 30 years. Here we benefit from several large clinical cohorts with multiple data types, including genetic and lifestyle information. This in combination with publically available multi-omics maps enables us to identify biomarkers of the clinical course and the response to existing therapies in a real-world setting, and to gain in-depth knowledge of distinct pathogenic pathways setting the stage for development of new interventions. To create strategic global synergies, MultipleMS includes 21 partners and covers not only the necessary clinical, biological, and computational expertise, but also includes six industry partners ensuring dissemination and exploitation of the methods and clinical decision support system. Moreover, the pharmaceutical industry partners provide expertise to ensure optimal selection and validation of clinically relevant biomarkers and new targets. Our conceptual personalized approach can readily be adapted to other immune-mediated diseases with a complex gene-lifestyle background and broad clinical spectrum with heterogeneity in treatment response. MultipleMS therefore goes significantly beyond current state-of-the-art thereby broadly affecting European policies, healthcare systems, innovation in translating big data and basic research into evidence-based personalized clinical applications.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores